Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 12Docetaxel 7durvalumab 5Gemcitabine 5Trastuzumab 4Radiotherapy 4Surveys and Questionnaires 3Magnetic Resonance Spectroscopy 3tremelimumab 2tisotumab vedotin 2pertuzumab 2motexafin gadolinium 2cemiplimab 2X-Rays 2TH 302 2Ritonavir 2Pemetrexed 2Nivolumab 2Ipilimumab 2Interviews as Topic 2Injections 2Immunoglobulin G 2Cryosurgery 2Cisplatin 2Bortezomib 2Biopsy 2Bariatric Surgery 2zenocutuzumab 1yeast-CEA vaccine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Depsipeptides × Head & Neck × Clear all
NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidNETOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Glioma, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Neuroendocrine Tumors, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡